Aethlon Medical (NASDAQ:AEMD) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a $7.00 price objective on the medical equipment provider’s stock.

Separately, StockNews.com began coverage on shares of Aethlon Medical in a report on Friday, November 8th. They set a “sell” rating for the company.

Aethlon Medical Stock Down 2.8 %

AEMD opened at $0.39 on Friday. The business’s fifty day simple moving average is $0.40 and its 200 day simple moving average is $0.48. Aethlon Medical has a 52 week low of $0.24 and a 52 week high of $2.35. The stock has a market cap of $5.42 million, a PE ratio of -0.14 and a beta of 1.74.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.